Related references
Note: Only part of the references are listed.Venetoclax in Previously Treated Waldenstrom Macroglobulinemia
Jorge J. Castillo et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for Waldenstrom's Macroglobulinemia: Final Analysis From the Randomized Phase III iNNOVATE Study
Christian Buske et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Long-Term Follow-Up of Ibrutinib Monotherapy in Symptomatic, Previously Treated Patients With Waldenstrom Macroglobulinemia
Steven P. Treon et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Partial response or better at six months is prognostic of superior progression-free survival in Waldenstrom macroglobulinaemia patients treated with ibrutinib
Jorge J. Castillo et al.
BRITISH JOURNAL OF HAEMATOLOGY (2021)
Bone marrow involvement and subclonal diversity impairs detection of mutated CXCR4 by diagnostic next-generation sequencing in Waldenstrom macroglobulinaemia
Joshua N. Gustine et al.
BRITISH JOURNAL OF HAEMATOLOGY (2021)
Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study
Anthony R Mato et al.
LANCET (2021)
Single-Agent Ibrutinib for Rituximab-Refractory Waldenstrom Macroglobulinemia: Final Analysis of the Substudy of the Phase III Innovate™ Trial
Judith Trotman et al.
CLINICAL CANCER RESEARCH (2021)
A prognostic index predicting survival in transformed Waldenstrom macroglobulinemia
Eric Durot et al.
HAEMATOLOGICA (2021)
Diagnostic Next-generation Sequencing Frequently Fails to Detect MYD88L265P in Waldenstrom Macroglobulinemia
Amanda Kofides et al.
HEMASPHERE (2021)
CXCR4 mutational status does not impact outcomes in patients with Waldenstrom macroglobulinemia treated with proteasome inhibitors
Jorge J. Castillo et al.
AMERICAN JOURNAL OF HEMATOLOGY (2020)
Diagnosis and treatment of autoimmune hemolytic anemia in adults: Recommendations from the First International Consensus Meeting
Ulrich Jaeger et al.
BLOOD REVIEWS (2020)
Cold agglutinin disease revisited: a multinational, observational study of 232 patients
Sigbjorn Berentsen et al.
BLOOD (2020)
Acalabrutinib monotherapy in patients with Waldenstrom macroglobulinemia: a single-arm, multicentre, phase 2 study
Roger G. Owen et al.
LANCET HAEMATOLOGY (2020)
Efficacy of Autologous and Allogeneic Hematopoietic Cell Transplantation in Waldenstrom Macroglobulinemia: A Systematic Review and Meta-analysis
Ricardo D. Parrondo et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2020)
A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenstrom macroglobulinemia: the ASPEN study
Constantine S. Tam et al.
BLOOD (2020)
Zanubrutinib for the treatment of patients with Waldenstrom macroglobulinemia: 3 years of follow-up
Judith Trotman et al.
BLOOD (2020)
Ixazomib, dexamethasone, and rituximab in treatment-naive patients with Waldenstrom macroglobulinemia: long-term follow-up
Jorge J. Castillo et al.
BLOOD ADVANCES (2020)
Systemic Amyloidosis due to Low-Grade Lymphoma
Ashutosh D. Wechalekar et al.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2020)
Management of AL amyloidosis in 2020
Giovanni Palladini et al.
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2020)
Zanubrutinib for the treatment of MYD88 wild-type Waldenstrom macroglobulinemia: a substudy of the phase 3 ASPEN trial
Meletios Dimopoulos et al.
BLOOD ADVANCES (2020)
Inhibition of Complement C1s with Sutimlimab in Patients with Cold Agglutinin Disease (CAD): Interim Results of the Phase 3 Cardinal Study Long-Term Follow-up
Alexander Roth et al.
BLOOD (2020)
Bendamustine Plus Rituximab for the Treatment of Waldenstrom Macroglobulinaemia: Patient Outcomes and Impact of Bendamustine Dosing
Suzanne O. Arulogun et al.
BLOOD (2020)
Bortezomib in Combination with Dexamethasone, Rituximab and Cyclophosphamide (B-DRC) As First - Line Treatment of Waldenstrom's Macroglobulinemia: Results of a Prospectively Randomized Multicenter European Phase II Trial
Christian Buske et al.
BLOOD (2020)
Response and Survival Outcomes to Ibrutinib Monotherapy for Patients With Waldenstrom Macroglobulinemia on and off Clinical Trials
Jorge J. Castillo et al.
HEMASPHERE (2020)
TP53 mutations are associated with mutated MYD88 and CXCR4, and confer an adverse outcome in Waldenstrom macroglobulinaemia
Joshua N. Gustine et al.
BRITISH JOURNAL OF HAEMATOLOGY (2019)
Importance of sequential analysis of TP53 variation in patients with Waldenstrom Macroglobulinaemia
Amy Christian et al.
BRITISH JOURNAL OF HAEMATOLOGY (2019)
A revised international prognostic score system for Waldenstrom's macroglobulinemia
Efstathios Kastritis et al.
LEUKEMIA (2019)
CXCR4 mutation subtypes impact response and survival outcomes in patients with Waldenstrom macroglobulinaemia treated with ibrutinib
Jorge J. Castillo et al.
BRITISH JOURNAL OF HAEMATOLOGY (2019)
Progression Risk Stratification of Asymptomatic Waldenstrom Macroglobulinemia
Mark Bustoros et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
How we manage Bing-Neel syndrome
Jorge J. Castillo et al.
BRITISH JOURNAL OF HAEMATOLOGY (2019)
Ibrutinib for the treatment of Bing-Neel syndrome: a multicenter study
Jorge J. Castillo et al.
BLOOD (2019)
Low risk of Pneumocystis jirovecii pneumonia and invasive aspergillosis in patients with Waldenstrom macroglobulinaemia on ibrutinib
Matthew P. Cheng et al.
BRITISH JOURNAL OF HAEMATOLOGY (2019)
Bendamustine plus rituximab in newly-diagnosed Waldenstrom macroglobulinaemia patients. A study on behalf of the French Innovative Leukaemia Organization (FILO)
Kamel Laribi et al.
BRITISH JOURNAL OF HAEMATOLOGY (2019)
Two Years Rituximab Maintenance Vs. Observation after First Line Treatment with Bendamustine Plus Rituximab (B-R) in Patients with Waldenstrom's Macroglobulinemia (MW): Results of a Prospective, Randomized, Multicenter Phase 3 Study (the StiL NHL7-2008 MAINTAIN trial)
Mathias J. Rummel et al.
BLOOD (2019)
Bone marrow biopsy in low-risk monoclonal gammopathy of undetermined significance reveals a novel smoldering multiple myeloma risk group
Mark Bustoros et al.
AMERICAN JOURNAL OF HEMATOLOGY (2019)
CXCR4S338X clonality is an important determinant of ibrutinib outcomes in patients with Waldenstrom macroglobulinemia
Joshua N. Gustine et al.
BLOOD ADVANCES (2019)
Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenstrom macroglobulinemia
Jonas Paludo et al.
ANNALS OF HEMATOLOGY (2018)
Treatment of IgM-associated immunoglobulin light-chain amyloidosis with rituximab-bendamustine
Richa Manwani et al.
BLOOD (2018)
Guideline for the treatment of chronic lymphocytic leukaemia: A British Society for Haematology Guideline
Anna H. Schuh et al.
BRITISH JOURNAL OF HAEMATOLOGY (2018)
Prospective Clinical Trial of Ixazomib, Dexamethasone, and Rituximab as Primary Therapy in Waldenstrom Macroglobulinemia
Jorge J. Castillo et al.
CLINICAL CANCER RESEARCH (2018)
Impact of ibrutinib dose intensity on patient outcomes in previously treated Waldenstrom macroglobulinemia
Jorge J. Castillo et al.
HAEMATOLOGICA (2018)
Highly sensitive MYD88(L265P) mutation detection by droplet digital polymerase chain reaction in Waldenstrom macroglobulinemia
Daniela Drandi et al.
HAEMATOLOGICA (2018)
Ibrutinib withdrawal symptoms in patients with Waldenstrom macroglobulinemia
Jorge J. Castillo et al.
HAEMATOLOGICA (2018)
Phase 3 Trial of Ibrutinib plus Rituximab in Waldenstrom's Macroglobulinemia
M. A. Dimopoulos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Impact of ibrutinib dose intensity on patient outcomes in previously treated Waldenstrom macroglobulinemia
Jorge J. Castillo et al.
HAEMATOLOGICA (2018)
Highly sensitive MYD88(L265P) mutation detection by droplet digital polymerase chain reaction in Waldenstrom macroglobulinemia
Daniela Drandi et al.
HAEMATOLOGICA (2018)
Ibrutinib withdrawal symptoms in patients with Waldenstrom macroglobulinemia
Jorge J. Castillo et al.
HAEMATOLOGICA (2018)
Predictors of symptomatic hyperviscosity in Waldenstrom macroglobulinemia
Jithma P. Abeykoon et al.
AMERICAN JOURNAL OF HEMATOLOGY (2018)
Ibrutinib Monotherapy in Symptomatic, Treatment-Naive Patients With Waldenstrom Macroglobulinemia
Steven P. Treon et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Autologous Stem Cell Transplant for IgM-Associated Amyloid Light-Chain Amyloidosis
M. Hasib Sidiqi et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2018)
Bortezomib overcomes the negative impact of CXCR4 mutations on survival of Waldenstrom macroglobulinemia patients
Romanos Sklavenitis-Pistofidis et al.
BLOOD (2018)
First report of ibrutinib in IgM-related amyloidosis: few responses, poor tolerability, and short survival
Tomas Pika et al.
BLOOD (2018)
MYD88 wild-type Waldenstrom Macroglobulinaemia: differential diagnosis, risk of histological transformation, andoverall survival
Steven P. Treon et al.
BRITISH JOURNAL OF HAEMATOLOGY (2018)
MYD88 mutation status does not impact overall survival in Waldenstrom macroglobulinemia
Jithma P. Abeykoon et al.
AMERICAN JOURNAL OF HEMATOLOGY (2018)
BDR in newly diagnosed patients with WM: final analysis of a phase 2 study after a minimum follow-up of 6 years
Maria Gavriatopoulou et al.
BLOOD (2017)
To select or not to select? The role of B-cell selection in determining the MYD88 mutation status in Waldenstrom Macroglobulinaemia
Joshua Gustine et al.
BRITISH JOURNAL OF HAEMATOLOGY (2017)
Guideline for the diagnosis, treatment and response criteria for Bing-Neel syndrome
Monique C. Minnema et al.
HAEMATOLOGICA (2017)
Guideline for the diagnosis, treatment and response criteria for Bing-Neel syndrome
Monique C. Minnema et al.
HAEMATOLOGICA (2017)
Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
Matthew S. Davids et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
TP53 Mutation and Its Prognostic Significance in Waldenstrom's Macroglobulinemia
Stephanie Poulain et al.
CLINICAL CANCER RESEARCH (2017)
Transformed Waldenstrom macroglobulinaemia: clinical presentation and outcome. A multi-institutional retrospective study of 77 cases from the French Innovative Leukemia Organization (FILO)
Eric Durot et al.
BRITISH JOURNAL OF HAEMATOLOGY (2017)
Dexamethasone, rituximab and cyclophosphamide for relapsed and/or refractory and treatment-naive patients with Waldenstrom macroglobulinemia
Jonas Paludo et al.
BRITISH JOURNAL OF HAEMATOLOGY (2017)
Bendamustine plus rituximab for chronic cold agglutinin disease: results of a Nordic prospective multicenter trial
Sigbjorn Berentsen et al.
BLOOD (2017)
Serum IgM level as predictor of symptomatic hyperviscosity in patients with Waldenstrom macroglobulinaemia
Joshua N. Gustine et al.
BRITISH JOURNAL OF HAEMATOLOGY (2017)
Investigation and management of IgM and Waldenstrom-associated peripheral neuropathies: recommendations from the IWWM-8 consensus panel
Shirley D'Sa et al.
BRITISH JOURNAL OF HAEMATOLOGY (2017)
Efficacy and long-term toxicity of the rituximab-fludarabine-cyclophosphamide combination therapy in Waldenstrom's macroglobulinemia
Laetitia Souchet et al.
AMERICAN JOURNAL OF HEMATOLOGY (2016)
Histological transformation to diffuse large B-cell lymphoma in patients with Waldenstrom macroglobulinemia
Jorge J. Castillo et al.
AMERICAN JOURNAL OF HEMATOLOGY (2016)
Treatment recommendations from the Eighth International Workshop on Waldenstrom's Macroglobulinemia
Veronique Leblond et al.
BLOOD (2016)
Recommendations for the diagnosis and initial evaluation of patients with Waldenstrom Macroglobulinaemia: A Task Force from the 8th International Workshop on Waldenstrom Macroglobulinaemia
Jorge J. Castillo et al.
BRITISH JOURNAL OF HAEMATOLOGY (2016)
Response rate to the treatment of Waldenstrom macroglobulinemia: A meta-analysis of the results of clinical trials
A. Santos-Lozano et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2016)
European Collaborative Study Defining Clinical Profile Outcomes and Novel Prognostic Criteria in Monoclonal Immunoglobulin M-Related Light Chain Amyloidosis
Sajitha Sachchithanantham et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
R2W: Subcutaneous Bortezomib, Cyclophosphamide and Rituximab (BCR) Versus Fludarabine, Cyclophosphamide and Rituximab (FCR) for Initial Therapy of WaldenstroM's Macroglobulinemia: A Randomised Phase II Study
Rebecca L. Auer et al.
BLOOD (2016)
Dexamethasone, rituximab, and cyclophosphamide as primary treatment of Waldenstrom macroglobulinemia: final analysis of a phase 2 study
Efstathios Kastritis et al.
BLOOD (2015)
Bendamustine and rituximab combination is safe and effective as salvage regimen in Waldenstrom macroglobulinemia
Alessandra Tedeschi et al.
LEUKEMIA & LYMPHOMA (2015)
Ibrutinib in Previously Treated Waldenstrom's Macroglobulinemia
Steven P. Treon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Extramedullary Waldenstrom macroglobulinemia
Ranjit Banwait et al.
AMERICAN JOURNAL OF HEMATOLOGY (2015)
Overall survival and competing risks of death in patients with Waldenstrom macroglobulinaemia: an analysis of the Surveillance, Epidemiology and End Results database
Jorge J. Castillo et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis
Zachary R. Hunter et al.
BLOOD (2014)
Treatment recommendations for patients with Waldenstrom macroglobulinemia (WM) and related disorders: IWWM-7 consensus
Meletios A. Dimopoulos et al.
BLOOD (2014)
Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenstrom macroglobulinemia
Steven P. Treon et al.
BLOOD (2014)
Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenstrom's macroglobulinemia
Steven P. Treon et al.
BLOOD (2014)
Elevated risk of venous but not arterial thrombosis in Waldenstrom macroglobulinemia/lymphoplasmacytic lymphoma
M. Hultcrantz et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2014)
Multiparameter flow cytometry for the identification of the Waldenstrom's clone in IgM-MGUS and Waldenstrom's Macroglobulinemia: new criteria for differential diagnosis and risk stratification
B. Paiva et al.
LEUKEMIA (2014)
Detection of MYD88 L265P in peripheral blood of patients with Waldenstrom's Macroglobulinemia and IgM monoclonal gammopathy of undetermined significance
L. Xu et al.
LEUKEMIA (2014)
Autologous Stem Cell Transplantation (ASCT) for the Treatment of Patients with Waldenstrom's Macroglobulinemia / Lymphoplasmacytic Lymphoma (WM/LPL). a Risk Factor Analysis By the European Society for Blood and Marrow Transplantation (EBMT) Lymphoma Working Party
Charalampia Kyriakou et al.
BLOOD (2014)
A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenstrom macroglobulinemia
Guang Yang et al.
BLOOD (2013)
Primary therapy of Waldenstrom macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN)
Meletios A. Dimopoulos et al.
BLOOD (2013)
Response assessment in Waldenstrom macroglobulinaemia: update from the VIth International Workshop
Roger G. Owen et al.
BRITISH JOURNAL OF HAEMATOLOGY (2013)
Immunoglobulin M Concentration in Waldenstrom Macroglobulinemia: Correlation With Bone Marrow B Cells and Plasma Cells
Ruth M. de Tute et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2013)
Patients With Waldenstrom Macroglobulinemia Commonly Present With Iron Deficiency and Those With Severely Depressed Transferrin Saturation Levels Show Response to Parenteral Iron Administration
Steven P. Treon et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2013)
Results of a Randomized Trial of Chlorambucil Versus Fludarabine for Patients With Untreated Waldenstrom Macroglobulinemia, Marginal Zone Lymphoma, or Lymphoplasmacytic Lymphoma
Veronique Leblond et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial
Mathias J. Rummel et al.
LANCET (2013)
Progression in smoldering Waldenstrom macroglobulinemia: long-term results
Robert A. Kyle et al.
BLOOD (2012)
Clinical and prognostic implications of low or high level of von Willebrand factor in patients with Waldenstrom macroglobulinemia
Benedicte Hivert et al.
BLOOD (2012)
Fludarabine plus cyclophosphamide and rituximab in Waldenstrom macroglobulinemia An Effective but Myelosuppressive Regimen to Be Offered to Patients With Advanced Disease
Alessandra Tedeschi et al.
CANCER (2012)
MYD88 L265P Somatic Mutation in Waldenstrom's Macroglobulinemia
Steven P. Treon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
The role of 18F-FDG PET/CT imaging in Waldenstrom macroglobulinemia
Ranjit Banwait et al.
AMERICAN JOURNAL OF HEMATOLOGY (2011)
Maintenance Rituximab is associated with improved clinical outcome in rituximab naive patients with Waldenstrom Macroglobulinaemia who respond to a rituximab-containing regimen
Steven P. Treon et al.
BRITISH JOURNAL OF HAEMATOLOGY (2011)
Factors Predicting Transformation of Asymptomatic IgM Monoclonal Gammopathy
Antonino Greco et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2011)
Heterogeneity of Histological Transformation Events in Waldenstrom's Macroglobulinemia (WM) and Related Disorders
R. G. Owen et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2011)
Novel M-Component Based Biomarkers in Waldenstrom's Macroglobulinemia
Xavier Leleu et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2011)
Bendamustine Therapy in Patients With Relapsed or Refractory Waldenstrom's Macroglobulinemia
Steven P. Treon et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2011)
Bone-marrow plasma cell burden correlates with IgM paraprotein concentration in Waldenstrom macroglobulinaemia
Sant-Rayn Pasricha et al.
JOURNAL OF CLINICAL PATHOLOGY (2011)
Weekly versus twice weekly bortezomib given in conjunction with rituximab, in patients with recurrent follicular lymphoma, mantle cell lymphoma and Waldenstrom macroglobulinaemia
Agathoclis Agathocleous et al.
BRITISH JOURNAL OF HAEMATOLOGY (2010)
IgA and IgG hypogammaglobulinemia in Waldenstrom's macroglobulinemia
Zachary R. Hunter et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
Allogeneic hematopoietic stem cell transplantation allows long-term complete remission and curability in high-risk Waldenstrom's macroglobulinemia. Results of a retrospective analysis of the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire
Alice Garnier et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
Phase II Trial of Weekly Bortezomib in Combination With Rituximab in Relapsed or Relapsed and Refractory Waldenstrom Macroglobulinemia
Irene M. Ghobrial et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
High-Dose Therapy and Autologous Stem-Cell Transplantation in Waldenstrom Macroglobulinemia: The Lymphoma Working Party of the European Group for Blood and Marrow Transplantation
Charalampia Kyriakou et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Long-term outcomes to fludarabine and rituximab in Waldenstrom macroglobulinemia
Steven P. Treon et al.
BLOOD (2009)
International prognostic scoring system for Waldenstrom macroglobulinemia
Pierre Morel et al.
BLOOD (2009)
High-dose therapy with autologous PBSC transplantation in the front-line treatment of Waldenstrom's macroglobulinemia
T. Caravita et al.
BONE MARROW TRANSPLANTATION (2009)
Quantitation of Serum Monoclonal Proteins: Relationship between Agarose Gel Electrophoresis and Immunonephelometry
David L. Murray et al.
CLINICAL CHEMISTRY (2009)
Primary Therapy of Waldenstrom Macroglobulinemia With Bortezomib, Dexamethasone, and Rituximab: WMCTG Clinical Trial 05-180
Steven P. Treon et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Assessment of Bone Marrow Response in Waldenstrom's Macroglobulinemia
Abraham M. Varghese et al.
CLINICAL LYMPHOMA & MYELOMA (2009)
Risk of lymphoproliferative disorders among first-degree relatives of lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia patients:: a population-based study in Sweden
Sigurdur Y. Kristinsson et al.
BLOOD (2008)
Serum-free light chain elevation is associated with a shorter time to treatment in Waldenstrom's macroglobulinemia
Raphael Itzykson et al.
HAEMATOLOGICA (2008)
The outcome of haemopoietic stem cell transplantation in the treatment of lymphoplasmacytic lymphoma in the UK: a British Society Bone Marrow Transplantation study
Maria H. Gilleece et al.
HEMATOLOGY (2008)
Serum immunoglobulin free light chain correlates with tumor burden markers in Waldenstrom macroglobulinemia
Xavier Leleu et al.
LEUKEMIA & LYMPHOMA (2008)
Evidence of graft-versus-Waldenstrom's macroglobulinaemia effect after allogeneic stem cell transplantation: a single centre experience
J. Stakiw et al.
BONE MARROW TRANSPLANTATION (2007)
Primary treatment of Waldenstrom macroglobulinemia with dexamethasone, rituximab, and cyclophosphamide
Meletios Athanasios Dimopoulos et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Long-term graft-versus-Waldenstrom macroglobulinemia effect following reduced intensity conditioning allogeneic stem cell transplantation
J-C Meniane et al.
BONE MARROW TRANSPLANTATION (2007)
Autologous stem cell transplantation as part of first-line treatment of Waldenstrom's macroglobulinemia
Peter Dreger et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2007)
Bortezomib is active in patients with untreated or relapsed Waldenstrom's macroglobulinemia: A phase II study of the National Cancer Institute of Canada Clinical Trials Group
Christine I. Chen et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Autologous or allogeneic stem cell transplantation in patients with Waldenstrom's macroglobulinemia
Athanasios Anagnostopoulos et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2006)
Characterization of familial Waldenstrom's macroglobulinemia
SP Treon et al.
ANNALS OF ONCOLOGY (2006)
Rituximab for primary chronic cold agglutinin disease: a prospective study of 37 courses of therapy in 27 patients
S Berentsen et al.
BLOOD (2004)
Initial immunoglobulin M 'Flare' after rituximab therapy in patients diagnosed with Waldenstrom macroglobulinemia an eastern cooperative oncology group study
IM Ghobrial et al.
CANCER (2004)
Waldenstrom macroglobulinemia involving extramedullary sites - Morphologic and immunophenotypic findings in 44 patients
P Lin et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2003)
Transplantation in Waldenstrom's macroglobulinemia - The French experience
O Tournilhac et al.
SEMINARS IN ONCOLOGY (2003)
Developing diagnostic criteria in Waldenstrom's macroglobulinemia
RG Owen
SEMINARS IN ONCOLOGY (2003)
Role for high-dose therapy with autologous hematopoietic stem cell support in Waldenstrom's macroglobulinemia
NC Munshi et al.
SEMINARS IN ONCOLOGY (2003)
Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia:: Consensus panel recommendations from the second international workshop on Waldenstrom's macroglobulinemia
RA Kyle et al.
SEMINARS IN ONCOLOGY (2003)
Long-term follow-up of IgM monoclonal gammopathy of undetermined significance
RA Kyle et al.
SEMINARS IN ONCOLOGY (2003)
Treatment of Waldenstrom's macroglobulinemia with rituximab
MA Dimopoulos et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Waldenstrom macroglobulinaemia:: presenting features and outcome in a series with 217 cases
R García-Sanz et al.
BRITISH JOURNAL OF HAEMATOLOGY (2001)
Multicenter, randomized comparative trial of fludarabine and the combination of cyclophosphamide-doxorubicin-prednisone in 92 patients with Waldenstrom macroglobulinemia in first relapse or with primary refractory disease
V Leblond et al.
BLOOD (2001)
Waldenstrom macroglobulinemia - Development of diagnostic criteria and identification of prognostic factors
RG Owen et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2001)
Share Paper
